Market Intelligence, Clinical Progress, and High-Purity Reagents for NKG2D-Based Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAET1E (ULBP4) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAET1E ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View RAET1E Products |
| Gene Delivery | RAET1E Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native membrane conformation. |
View RAET1E Products |
| Benchmark Ab | Anti-RAET1E Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View RAET1E Products |
| Validator | RAET1E siRNA Set For knockdown verification in target-specific validation assays. |
View RAET1E Products |
| Related Target A | NKG2D (KLRK1) Primary receptor for RAET1E; critical for evaluating receptor-ligand interactions and competitive blocking. |
View NKG2D Products |
| Related Target B | MICA Co-ligand for NKG2D; essential for specificity and cross-reactivity counter-screening. |
View MICA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding-Resistant Screening (Soluble vs. Membrane-bound form) | Recombinant RAET1E ECD-Fc fusion proteins expressed in HEK293 to ensure native post-translational modifications. |
| NKG2D Binding Competition and Cross-reactivity | High-purity recombinant NKG2D and alternative ligands (MICA/B) for robust multi-ligand competitive ELISA/SPR assays. |
| Lack of Validated Reference Controls | Sequence-verified clinical benchmark antibodies available as research-grade biosimilars. |
| False Positives in High-Throughput Screens | Highly specific RAET1E siRNA pool included to validate target-dependent functional responses in cell-based assays. |
Live RAET1E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAET1E (ULBP4) therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK-cell engagers and CAR-NK cell therapies. As first-generation NKG2D-ligand therapies reach the clinic, the next wave of R&D is targeting the prevention of RAET1E shedding—a major mechanism of tumor immune evasion—and developing bispecific molecules that selectively tether RAET1E to tumor surfaces to enhance NK cell-mediated cytotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific / NK Engager | Innate Pharma, Affimed | Hematological Malignancies, Solid Tumors | Heterodimer Validation (Requires high-purity RAET1E ECD and recombinant NKG2D) |
| CAR-T / CAR-NK | Celyad Oncology, Nkarta Therapeutics | Colorectal Cancer, AML | Target Cell Line Construction (Requires Lentivirus for stable RAET1E overexpression) |
| Monoclonal Antibody (Shedding Blockers) | Academic Institutes, Biotech Startups | Advanced Solid Tumors | Shedding Assay (Requires sequence-verified RAET1E and benchmark control antibodies) |